Sunshine Biopharma Reports Officer/Director Changes, Compensation on Jan 25

TL;DR

**SBFM filed an 8-K about leadership changes and pay, keep an eye on future strategy.**

AI Summary

Sunshine Biopharma, Inc. (SBFM) filed an 8-K on January 30, 2024, reporting an event on January 25, 2024, related to the departure or election of directors/officers and their compensatory arrangements. The filing indicates that the company's Common Stock (SBFM) and Common Stock Purchase Warrants (SBFMW) are registered on The Nasdaq Stock Market LLC. This matters to investors because changes in leadership and compensation structures can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.

Why It Matters

Changes in executive leadership and their compensation can influence a company's strategic direction and operational efficiency, directly affecting investor confidence and stock valuation.

Risk Assessment

Risk Level: medium — Changes in leadership can introduce uncertainty, but the filing itself doesn't detail specific negative events, making it a moderate risk.

Analyst Insight

Investors should monitor future filings or company announcements for specific details regarding the leadership changes and compensation arrangements mentioned, as these could provide clearer insights into the company's strategic direction and stability.

Key Numbers

• $0.001 — Common Stock par value (This is the nominal value per share of Sunshine Biopharma's common stock.)

Key Players & Entities

• Sunshine Biopharma, Inc. (company) — registrant
• The Nasdaq Stock Market LLC (company) — exchange where SBFM and SBFMW are registered
• January 25, 2024 (date) — date of earliest event reported
• January 30, 2024 (date) — filing date of the 8-K
• $0.001 (dollar_amount) — par value of Common Stock

Forward-Looking Statements

• Sunshine Biopharma will provide more specific details regarding the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' in a subsequent filing or press release. (Sunshine Biopharma, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC

Filing Documents

• sunshine_8k.htm (8-K) — 30KB
• 0001683168-24-000540.txt ( ) — 242KB
• sbfm-20240125.xsd (EX-101.SCH) — 3KB
• sbfm-20240125_def.xml (EX-101.DEF) — 26KB
• sbfm-20240125_lab.xml (EX-101.LAB) — 36KB
• sbfm-20240125_pre.xml (EX-101.PRE) — 25KB
• sunshine_8k_htm.xml (XML) — 5KB

02 Departure of Directors or Principal Officers;

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On January 25, 2024, the Board of Directors of Sunshine Biopharma, Inc. ("we", "us," "our" or the "Company") held its annual meeting. At the meeting the following persons were elected to the following positions: Name Position Dr. Steve N. Slilaty President and Chief Executive Officer Dr. Abderrazzak Merzouki Chief Science Officer Mr. Camille Sebaaly Chief Financial Officer and Secretary Mr. Marc Beaudoin Chief Operating Officer Mr. Malek Chamoun Chief Development Officer Each of the aforesaid persons shall serve until the next annual meeting of the Board of Directors, their resignation or until their successors have been elected and qualified. Previously, Dr. Merzouki had held the position of Chief Operating Officer. Mr. Beaudoin and Mr. Chamoun are new officers. The other officers are continuing in their prior positions. Mr. Chamoun is also currently President of the Company's wholly owned subsidiary, Nora Pharma Inc. The resumes of the Company's new officers are as follows: Malek Chamoun, age 39 , was appointed as our Chief Development Officer in January 2024. In 2017 he founded Nora Pharma Inc., a Canadian pharmaceutical company ("Nora Pharma"), based in Montreal, where he has been the President and CEO since inception. We acquired Nora Phara in October 2022. Mr. Chamoun received a bachelor's degree in business administration from Hautes tudes Commerciales, Montreal, Quebec, Canada in 2008 and became a licensed CPA in Canada in 2012. He devotes all of his business time to Nora's affairs. Marc Beaudoin, age 57, was appointed as our Chief Operating Officer in January 2024. Mr. Beaudoin has been self-employed as a business strategy consultant, primarily in the pharmaceutical and biopharmaceutical sectors, since 2016. From 2006 to 2016, he held several executive positions at Sandoz Canada in various areas including Marketing and

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 30, 2024 SUNSHINE BIOPHARMA, INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR